Justin Stebbing

Justin Stebbing has a diverse work experience in the healthcare and biomedical fields. Justin currently serves as a Scientific Advisor to Clinical Ink, a company focused on simplifying and accelerating clinical studies through innovative technologies. Justin is also the Chair of the Scientific Advisory Board at Zephyr AI, a healthcare technology company using artificial intelligence to revolutionize drug discovery and precision medicine. Justin is a Consultant Oncologist at Phoenix Hospital Group, specializing in second opinions. Justin holds several leadership positions, including Head of Strategy, Board Member, and SAB Chair at Onconox. Justin is also actively involved in academic research and education, serving as a Visiting Professor at Imperial College London and a Professor of Biomedical Sciences at Anglia Ruskin University. Justin has expertise in medical strategy as the Lead Medical Strategist at Equilibre and has worked as an Analyst at Vitruvian Partners. Additionally, Justin has contributed as a Scientific Advisor at BenevolentAI, where they focused on the impact of the pandemic on healthcare. Justin is also dedicated to mental health support and serves as a Listening Volunteer at The Listening Place, a charitable organization providing confidential and compassionate support to individuals struggling with mental health.

Justin Stebbing obtained a BM BCh MA (oxon) FRCP FRCPath PhD MD degree in Medicine from the University of Oxford from 1989 to 1995. Justin then pursued further education at The Johns Hopkins University School of Medicine from 1996 to 1999, where they completed a residency in Internal Medicine. Following that, they attended Imperial College London from 1999 to 2002 and obtained a Doctor of Philosophy (PhD) in Medicine and Immunology. Justin Stebbing also obtained additional certifications, including FRCPath from the Royal College of Pathologists (RCPath) in 2007, FRCP from the Royal College of Physicians in 2006, PhD from Imperial College London in 2003, and BM BCh MA from the University of Oxford in 1995.